Vaccine focusing to cross-subtype HIV-1 gp120 variable loop epitopes.

[1]  D. Montefiori,et al.  Spectrum of HIV antibodies in vaccine and disease. , 2014, Current opinion in HIV and AIDS.

[2]  Gary J. Nabel,et al.  Vaccine-Induced Env V1-V2 IgG3 Correlates with Lower HIV-1 Infection Risk and Declines Soon After Vaccination , 2014, Science Translational Medicine.

[3]  A. Statnikov,et al.  Computational Prediction of Neutralization Epitopes Targeted by Human Anti-V3 HIV Monoclonal Antibodies , 2014, PloS one.

[4]  Gary J. Nabel,et al.  Vaccine-Induced IgG Antibodies to V1V2 Regions of Multiple HIV-1 Subtypes Correlate with Decreased Risk of HIV-1 Infection , 2014, PloS one.

[5]  N. Haigwood,et al.  Improvement of antibody responses by HIV envelope DNA and protein co-immunization. , 2014, Vaccine.

[6]  N. Michael,et al.  HIV-1 variable loop 2 and its importance in HIV-1 infection and vaccine development. , 2013, Current HIV research.

[7]  Gerald R. Nakamura,et al.  Monoclonal Antibodies to the V2 Domain of MN-rgp120: Fine Mapping of Epitopes and Inhibition of α4β7 Binding , 2012, PloS one.

[8]  Guido Ferrari,et al.  Immune-correlates analysis of an HIV-1 vaccine efficacy trial. , 2012, The New England journal of medicine.

[9]  D. Baker,et al.  Computation-Guided Backbone Grafting of a Discontinuous Motif onto a Protein Scaffold , 2011, Science.

[10]  Pham Phung,et al.  Broad neutralization coverage of HIV by multiple highly potent antibodies , 2011, Nature.

[11]  S. Zolla-Pazner,et al.  Cross-Clade HIV-1 Neutralizing Antibodies Induced with V3-Scaffold Protein Immunogens following Priming with gp120 DNA , 2011, Journal of Virology.

[12]  M. Humbert,et al.  An Anti-HIV-1 V3 Loop Antibody Fully Protects Cross-Clade and Elicits T-Cell Immunity in Macaques Mucosally Challenged with an R5 Clade C SHIV , 2011, PloS one.

[13]  S. Zolla-Pazner,et al.  Comparative Magnitude of Cross-Strain Conservation of HIV Variable Loop Neutralization Epitopes , 2010, PloS one.

[14]  R. Abagyan,et al.  Structure-guided design and immunological characterization of immunogens presenting the HIV-1 gp120 V3 loop on a CTB scaffold. , 2010, Virology.

[15]  D. Baker,et al.  Elicitation of structure-specific antibodies by epitope scaffolds , 2010, Proceedings of the National Academy of Sciences.

[16]  L. Stamatatos,et al.  Computational design of epitope-scaffolds allows induction of antibodies specific for a poorly immunogenic HIV vaccine epitope. , 2010, Structure.

[17]  Allan C. deCamp,et al.  Magnitude and breadth of a nonprotective neutralizing antibody response in an efficacy trial of a candidate HIV-1 gp120 vaccine. , 2010, The Journal of infectious diseases.

[18]  Mario Roederer,et al.  Rational Design of Envelope Identifies Broadly Neutralizing Human Monoclonal Antibodies to HIV-1 , 2010, Science.

[19]  Timothy Cardozo,et al.  Conserved structural elements in the V3 crown of HIV-1 gp120 , 2010, Nature Structural &Molecular Biology.

[20]  D. Follmann,et al.  Neutralizing antibody titers conferring protection to macaques from a simian/human immunodeficiency virus challenge using the TZM-bl assay. , 2010, AIDS research and human retroviruses.

[21]  Holly Janes,et al.  Tiered Categorization of a Diverse Panel of HIV-1 Env Pseudoviruses for Assessment of Neutralizing Antibodies , 2009, Journal of Virology.

[22]  S. Zolla-Pazner,et al.  Structural basis of the cross-reactivity of genetically related human anti-HIV-1 mAbs: implications for design of V3-based immunogens. , 2009, Structure.

[23]  S. Zolla-Pazner,et al.  Anti-V3 Monoclonal Antibodies Display Broad Neutralizing Activities against Multiple HIV-1 Subtypes , 2009, PloS one.

[24]  Pham Phung,et al.  Broad and Potent Neutralizing Antibodies from an African Donor Reveal a New HIV-1 Vaccine Target , 2009, Science.

[25]  S. Zolla-Pazner,et al.  Cross-clade neutralizing antibodies against HIV-1 induced in rabbits by focusing the immune response on a neutralizing epitope. , 2009, Virology.

[26]  Yih-En Andrew Ban,et al.  Challenges for structure-based HIV vaccine design , 2009, Current opinion in HIV and AIDS.

[27]  R. Wyatt,et al.  Immunogenicity of HIV-1 envelope glycoprotein oligomers , 2009, Current opinion in HIV and AIDS.

[28]  S. Zolla-Pazner,et al.  Worldwide distribution of HIV type 1 epitopes recognized by human anti-V3 monoclonal antibodies. , 2009, AIDS research and human retroviruses.

[29]  Richard T. Wyatt,et al.  Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals , 2009, Nature.

[30]  D. Barouch,et al.  Challenges in the development of an HIV-1 vaccine , 2008, Nature.

[31]  S. Zolla-Pazner,et al.  Focusing the immune response on the V3 loop, a neutralizing epitope of the HIV-1 gp120 envelope. , 2008, Virology.

[32]  Punnee Pitisuttithum,et al.  Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. , 2006, The Journal of infectious diseases.

[33]  Feng Gao,et al.  Genetic and Neutralization Properties of Subtype C Human Immunodeficiency Virus Type 1 Molecular env Clones from Acute and Early Heterosexually Acquired Infections in Southern Africa , 2006, Journal of Virology.

[34]  S. Zolla-Pazner,et al.  Cross-Clade Neutralizing Activity of Human Anti-V3 Monoclonal Antibodies Derived from the Cells of Individuals Infected with Non-B Clades of Human Immunodeficiency Virus Type 1 , 2006, Journal of Virology.

[35]  S. Zolla-Pazner,et al.  Factors Determining the Breadth and Potency of Neutralization by V3-Specific Human Monoclonal Antibodies Derived from Subjects Infected with Clade A or Clade B Strains of Human Immunodeficiency Virus Type 1 , 2006, Journal of Virology.

[36]  S. Zolla-Pazner,et al.  Crystal Structures of Human Immunodeficiency Virus Type 1 (HIV-1) Neutralizing Antibody 2219 in Complex with Three Different V3 Peptides Reveal a New Binding Mode for HIV-1 Cross-Reactivity , 2006, Journal of Virology.

[37]  S. Zolla-Pazner.  Improving on nature: focusing the immune response on the V3 loop. , 2006, Human antibodies.

[38]  R. Doms,et al.  Comparing Antigenicity and Immunogenicity of Engineered gp120 , 2005, Journal of Virology.

[39]  Xiping Wei,et al.  Human Immunodeficiency Virus Type 1 env Clones from Acute and Early Subtype B Infections for Standardized Assessments of Vaccine-Elicited Neutralizing Antibodies , 2005, Journal of Virology.

[40]  Kenneth H Mayer,et al.  Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. , 2005, The Journal of infectious diseases.

[41]  Michael G Hudgens,et al.  Correlation between immunologic responses to a recombinant glycoprotein 120 vaccine and incidence of HIV-1 infection in a phase 3 HIV-1 preventive vaccine trial. , 2005, The Journal of infectious diseases.

[42]  Robyn L Stanfield,et al.  Structural rationale for the broad neutralization of HIV-1 by human monoclonal antibody 447-52D. , 2004, Structure.

[43]  N. Haigwood,et al.  Transfer of neutralizing IgG to macaques 6 h but not 24 h after SHIV infection confers sterilizing protection: Implications for HIV-1 vaccine development , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[44]  D. Francis,et al.  Candidate HIV/AIDS vaccines: lessons learned from the World's first phase III efficacy trials , 2003, AIDS.

[45]  C. Cheng‐Mayer,et al.  Antibody Protects Macaques against Vaginal Challenge with a Pathogenic R5 Simian/Human Immunodeficiency Virus at Serum Levels Giving Complete Neutralization In Vitro , 2001, Journal of Virology.

[46]  J. Mascola,et al.  The Ability of an Oligomeric Human Immunodeficiency Virus Type 1 (HIV-1) Envelope Antigen To Elicit Neutralizing Antibodies against Primary HIV-1 Isolates Is Improved following Partial Deletion of the Second Hypervariable Region , 2001, Journal of Virology.

[47]  J. Mascola,et al.  Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies , 2000, Nature Medicine.

[48]  Tahir A. Rizvi,et al.  Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian–human immunodeficiency virus infection , 2000, Nature Medicine.

[49]  J. Mascola,et al.  Protection of Macaques against Pathogenic Simian/Human Immunodeficiency Virus 89.6PD by Passive Transfer of Neutralizing Antibodies , 1999, Journal of Virology.

[50]  S. Zolla-Pazner,et al.  Passive immunization with a human immunodeficiency virus type 1-neutralizing monoclonal antibody in Hu-PBL-SCID mice: isolation of a neutralization escape variant. , 1998, The Journal of infectious diseases.

[51]  C. Barbas,et al.  Passive immunization with a human monoclonal antibody protects hu-PBL-SCID mice against challenge by primary isolates of HIV-1 , 1997, Nature Medicine.

[52]  I. Roitt,et al.  Can epitope-focused vaccines select advantageous immune responses? , 1997, Molecular medicine today.

[53]  C. Barbas,et al.  Protection against HIV‐1 infection in hu‐PBL-SCID mice by passive immunization with a neutralizing human monoclonal antibody against the gp120 CD4‐binding site , 1995, AIDS.

[54]  J. Safrit,et al.  Pre- and postexposure protection against human immunodeficiency virus type 1 infection mediated by a monoclonal antibody. , 1995, The Journal of infectious diseases.

[55]  D. Nixon,et al.  Cellular and humoral antigenic epitopes in HIV and SIV. , 1992, Immunology.

[56]  K. Murthy,et al.  Prevention of HIV infection by passive immunization with HIV immunoglobulin. , 1991, AIDS research and human retroviruses.

[57]  J. Albert,et al.  Rapid development of isolate-specific neutralizing antibodies after primary HIV-1 infection and consequent emergence of virus variants which resist neutralization by autologous sera. , 1990, AIDS.

[58]  Robin A. Weiss,et al.  Neutralization of human T-lymphotropic virus type III by sera of AIDS and AIDS-risk patients , 1985, Nature.

[59]  D Sydman,et al.  Placebocontrolled Phase 3 Trial of a Recombinant Glycoprotein 120 Vaccine to Prevent HIV-1 InfectionGurwith M, for the rgp 120 HIV Vaccine Study Group (VaxGen, Brisbane, Calif; et al) J Infect Dis 191:654–665, 2005§ , 2006 .

[60]  R. Rappuoli.  Reverse vaccinology : Genomics , 2000 .

[61]  R. Desrosiers,et al.  Envelope sequence variation, neutralizing antibodies, and primate lentivirus persistence. , 1994, Current topics in microbiology and immunology.